ASND vs EVO
Ascendis Pharma A/S and Evotec SE, side by side — 6 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | EVO |
|---|---|---|
| Revenue | €720.1M | €797.0M |
| Net income | €-228.0M | €-196.1M |
| Gross margin | 86.8% | 14.4% |
| Net margin | −31.7% | −24.6% |
| Return on equity | · | −18.9% |
| Diluted EPS | −€3.76 | −€1.11 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-99.2M |
| Equity | · | €952.5M |
| Net debt / equity | · | −0.02× |
| Current ratio | 1.04× | 1.98× |
| Revenue CAGR 5y | 153.0% | 12.3% |
| Profit CAGR 5y | · | · |
ASND and EVO book revenue within 15% of each other, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
6 years side by side
| Fiscal year | ASND | EVO |
|---|---|---|
| FY2024 | €363.6M | €797.0M |
| FY2023 | €266.7M | €781.4M |
| FY2022 | €51.2M | €751.4M |
| FY2021 | €7.8M | €618.0M |
| FY2020 | €7.0M | €500.9M |
| FY2019 | €13.4M | €446.4M |
Bottom line
| Fiscal year | ASND | EVO |
|---|---|---|
| FY2024 | €-378.1M | €-196.1M |
| FY2023 | €-481.4M | €-83.9M |
| FY2022 | €-583.2M | €-175.7M |
| FY2021 | €-383.6M | €215.5M |
| FY2020 | €-419.0M | €6.3M |
| FY2019 | €-218.0M | €38.2M |
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −€433,326,000 | EVO |
| FY2023 | −€514,708,000 | EVO |
| FY2022 | −€700,274,000 | EVO |
| FY2021 | −€610,256,000 | EVO |
| FY2020 | −€493,971,000 | EVO |
| FY2019 | −€433,062,000 | EVO |
EVO has reported the higher revenue in every one of these 6 fiscal years. The gap has widened since the earliest year compared.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than EVO's over the 3 comparable fiscal years — 471.2 percentage points of standard deviation against 6.3.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
EVO led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than EVO's over the 4 comparable fiscal years — 22.6 percentage points of standard deviation against 12.3.
4 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
EVO led in return on equity in every one of the 4 comparable fiscal years — a structural lead, not a recent swing.
4 of 10 comparable fiscal years — a year missing data on either side is not counted.